Business Context and Reporting Period
Company: Bristol-Myers Squibb Company
Filing Type: Form 8-K (Current Report)
Date of Report: May 9, 2005
Context: This filing announces the submission of a revised 2005 first-quarter Form 10-Q to the SEC. The revision addresses additional litigation reserves recorded after the initial first-quarter financial results were announced on April 28, 2005.
Key Financial Metrics
- Pre-tax Earnings Adjustment: Reduced by $110 million due to additional litigation reserves.
- Total Reserves for Disclosed Matters: $140 million (as reported in the revised Form 10-Q).
- Specific Matters: Wholesaler inventory and certain other accounting matters.
- Other Metrics: The filing text does not provide clear values for total revenue, net profit, cash flow, margins, debt, or liquidity for the period.
Material Changes Versus Prior Period
The primary material change is a downward revision to pre-tax earnings of $110 million compared to the figures initially reported on April 28, 2005. This adjustment reflects the recording of additional reserves for previously disclosed litigation and accounting matters.
Guidance, Outlook, and Risks
Management Commentary: The company issued a press release (Exhibit 99.1) confirming the filing of the revised Form 10-Q. No specific forward-looking guidance or outlook was detailed in this 8-K text.
Risks and Contingencies: The filing highlights ongoing contingencies related to wholesaler inventory and other accounting matters, necessitating increased litigation reserves.
Important Facts for Investor Verification
- Verify the specific details of the revised 2005 first-quarter Form 10-Q filed on May 9, 2005.
- Confirm the breakdown of the $140 million total reserves between wholesaler inventory and other accounting matters.
- Assess the impact of the $110 million pre-tax earnings reduction on the company's overall financial position and future guidance.